CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma

World Journal of Urology

Volumn 30, Issue 4, 2012, Pages 553-558

  da Costa, Walter Henriques ^a   Rocha, Rafael Malagoli ^a   da Cunha, Isabela Werneck ^a   da Fonseca, Francisco Paula ^a   Guimaraes, Gustavo Cardoso ^a   Zequi, Stenio de Cassio ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

CD133 antigen; Kidney; Molecular markers; Renal carcinoma

Indexed keywords

EID: 84864535026     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0769-x     Document Type: Article

References (30)

1. American Cancer Society (2010) Cancer facts & figures 2010. American Cancer Society, Atlanta.
2. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34: 193-205.
3. Kanao K, Mizuno R, Kikuchi E et al (2009) Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification. J Urol 181: 480-485.
4. Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical. Eur Urol 55: 851-863.
5. Park CH, Bergsagel DE, McCulloch EA (1971) Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 46: 411-422.
6. Hombach-Klonisch S, Paranjothy T, Wiechec E et al (2008) Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch ImmunolTher Exp 56: 165-180.
7. Bussolati B, Bruno S, Grange C et al (2005) Isolation of renal progenitor cells from adult human kidney. Am J Pathol 166: 545-555.
8. Röper K, Corbeil D, Huttner WB (2000) Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat Cell Biol 2: 582-592.
9. Corbeil D, Röper K, Fargeas CA, Joester A, Huttner WB (2001) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2: 82-91.
10. Weigmann A, Corbeil D, Hellwig A, Huttner WB (1997) Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc NatlAcadSci 94: 12425-12430.
11. D'Alterio C et al (2010) Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 9: 4491-4492.
12. Budwit-Novotny DA, McCarty KS, Cox EB et al (1986) Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46(10): 5419-5425.
13. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H (2005) Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 173: 1889-1892.
14. Bedke J, Pritsch M, Buse S et al (2008) Prognostic stratification of localized renal cell carcinoma by tumor size. J Urol 180: 62-67.
15. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98: 1331-1334.
16. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC (2008) Renal mass biopsy-a renaissance? J Urol 179: 20-27.
17. Klatte T, Seligson DB, LaRochelle J et al (2009) Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 18: 894-900.
18. Mizrak D, Brittan M, Alison MR (2008) CD133: molecule of the moment. J Pathol 214: 3-9.
19. Sagrinati C, Netti GS, Mazzinghi B et al (2006) Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 17: 2443-2456.
20. Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, Ferrando U, Camussi G (2006) CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 169(6): 2223-2235.
21. Dall'Oglio MF, Antunes AA, Sarkis AS et al (2007) Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int 100: 552-555.
22. Dall'Oglio MF, Ribeiro-Filho LA, Antunes AA et al (2007) Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. J Urol 178: 425-428.
23. May M, Brookman-Amissah S, Kendel F et al (2009) Validation of a postoperative prognostic model consisting of tumor microvascular invasion, size, and grade to predict disease-free and cancer-specific survival of patients with surgically resected renal cell carcinoma. Int J Urol 16: 616-621.
24. Kume H, Suzuki M, Fujimura T et al (2010) Distant metastasis of renal cell carcinoma with a diameter of 3 cm or less-which is aggressive cancer? J Urol 184: 64-68.
25. Jeon Y et al (2010) Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers. World J Gastroenterol 16(25): 3153.
26. Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y (2009) CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. Pancreas 38(8): e207-e214.
27. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP (2010) The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70(2): 719-729.
28. Balch C, Nephew KP, Huang TH, Bapat SA (2007) Epigenetic "bi-valently marked" process of cancer stem cell-driven tumorigenesis. Bioessays 29: 842-845.
29. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG, Baylin SB (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.
30. Mathieu J et al (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71: 4640-4652.